Page last updated: 2024-10-27

gabexate and Neuroleptic Malignant Syndrome

gabexate has been researched along with Neuroleptic Malignant Syndrome in 1 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Research Excerpts

ExcerptRelevanceReference
"The status epilepticus was also attenuated by the use of thiamylal sodium."1.30[A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation]. ( Miyoshi, T; Motomura, S; Osoegawa, M; Tamura, K; Yamanaka, H, 1999)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Osoegawa, M1
Motomura, S1
Yamanaka, H1
Tamura, K1
Miyoshi, T1

Other Studies

1 other study available for gabexate and Neuroleptic Malignant Syndrome

ArticleYear
[A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation].
    Rinsho shinkeigaku = Clinical neurology, 1999, Volume: 39, Issue:6

    Topics: Anticoagulants; Antiparkinson Agents; Bromocriptine; Dantrolene; Disseminated Intravascular Coagulat

1999